-
公开(公告)号：US10323061B2
公开(公告)日：2019-06-18
申请号：US15439531
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Jing He , Guoqiang Wang , Xuechao Xing
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US20180362501A1
公开(公告)日：2018-12-20
申请号：US15988763
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Brett Granger , Ruichao Shen , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D491/107 , C07D498/08 , C07D401/04
CPC classification number: C07D401/14 , C07D401/04 , C07D491/107 , C07D498/08
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10138228B2
公开(公告)日：2018-11-27
申请号：US15597423
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Yong He , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Jiang Long , Guoqiang Wang
IPC: A61K31/42 , C07D413/12
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20180327388A1
公开(公告)日：2018-11-15
申请号：US15979128
申请日：2018-05-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D405/14 , C07D403/12 , C07D403/14 , C07D413/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10080741B2
公开(公告)日：2018-09-25
申请号：US15497268
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Brett Granger , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: C07D261/08 , C07D413/12 , A61K31/42 , C07D261/06 , C07D413/04
CPC classification number: A61K31/42 , C07D261/06 , C07D261/08 , C07D413/04 , C07D413/12
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
Patent Agency Ranking
公开(公告)号：US20170304271A1
公开(公告)日：2017-10-26
申请号：US15497307
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: A61K31/42 , C07D277/62 , C07D275/04 , C07D261/08 , A61K31/64 , A61K31/545 , A61K31/4725 , C07D413/12 , A61K31/426
CPC classification number: A61K31/42 , A61K31/426 , A61K31/4725 , A61K31/545 , A61K31/64 , C07D261/08 , C07D275/04 , C07D277/62 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170240585A1
公开(公告)日：2017-08-24
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
CPC classification number: C07J41/0055 , C07B59/007 , C07B2200/05 , C07J9/005 , C07J17/00 , C07J43/003 , C07J51/00
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US12018017B2
公开(公告)日：2024-06-25
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
59.发明公开公开(公告)号：US20240132476A1
公开(公告)日：2024-04-25
申请号：US18383949
申请日：2023-10-25
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US11958879B2
公开(公告)日：2024-04-16
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
CPC classification number: C07J43/003 , C07J41/005 , C07J41/0055 , C07J41/0088 , C07J9/00 , C07J9/005 , C07J51/00
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,
The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.022 seconds)
